RxDoctor Payments Data

Antreas Hindoyan, MD

Interventional Cardiology · Los Angeles, CANPI 1477857290

Payments from drug & device makers

$54,846in general payments, 2019–2025

Across 216 payments — averaging $253.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cathworks, Inc.$21K
  • Shockwave Medical, Inc$20K
  • Boston Scientific$8K
  • Abiomed$4K
  • Abbott$910
  • Medtronic$853
  • plus $550 from 11 others

What the payments were for

  • Consulting fees$12,50023%
  • Speaking & faculty fees$22,60041%
  • Travel & lodging$5,80411%
  • Food & beverage$13,91625%
  • Education$250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,846 in reported general payments places this provider in the 75th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$293,144
Medicare patients
1,310
Services billed
2,595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban254$245,118
EntrestoSacubitril/Valsartan196$159,522
Repatha SureclickEvolocumab49$45,088
OzempicSemaglutide27$33,650
VascepaIcosapent Ethyl46$24,551
XareltoRivaroxaban18$20,000
Praluent PenAlirocumab25$12,721
MultaqDronedarone Hcl13$10,662
Metoprolol Succinate581$5,609
Ranolazine ErRanolazine80$5,605
LotrelAmlodipine Besylate/Benazepril11$4,205
Icosapent Ethyl22$3,011
Atorvastatin Calcium313$2,757
Rosuvastatin Calcium221$2,535
Losartan Potassium298$2,403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$15$159,522196 claims
Johnson & JohnsonXarelto$125$20,00018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →